Bracco’s cell selection and activation microbubble technology is designed to support both positive- and negative-selection strategies.

Press ReleaseIB Communicationsbracco@ibcomms.agency Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation TechnologiesTechnology based on Bracco’s clinically validated ...

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data ...

The agreement grants Repertoire an upfront payment of $85m, with the possibility of up to $1.84bn in additional milestone ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Dr. Shune continues the case discussion by describing disease progression following second-line therapy and outlining her approach to third-line treatment selection in cGVHD. After initiating systemic ...

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with BeOne Medicines, a global oncology company.

A 52-year-old woman experiences chronic GvHD post-stem cell transplant, showcasing complex symptoms and treatment challenges. Discover her journey and management strategies. Dr. Shune discusses how ...

Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine ...